Pharmarise Holdings Corp. said its normalized net income for the fiscal third quarter ended Feb. 28 was ¥12.71 per share, a decrease of 38.0% from ¥20.51 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥116.3 million, a decrease of 27.2% from ¥159.6 million in the year-earlier period.
The normalized profit margin dropped to 1.2% from 1.7% in the year-earlier period.
Total revenue climbed 5.2% on an annual basis to ¥9.92 billion from ¥9.43 billion, and total operating expenses increased 6.8% year over year to ¥9.67 billion from ¥9.05 billion.
Reported net income decreased 49.0% from the prior-year period to ¥44.8 million, or ¥4.90 per share, from ¥87.9 million, or ¥11.29 per share.
As of April 14, US$1 was equivalent to ¥119.09.
